Vendor comparison · 2026
Follistatin-344 vendors: 3 compared on COAs and price
Tissue & recoveryAlso known as FS-344, Follistatin
Evidence tier
Substantial published literature
1,215 publications over 39 years · trials not yet curated
- Vendors carrying it
- 3
- 3 with a listed price
- Vendors with checkable COAs
- 0
- 0 publish any certificate
- Lots tested
- 0
- 0 naming a checkable lab
- Independent assays
- 0
- none on file yet
- Newest assay
- —
- Laboratories named
- 0
- Median label gap
- —
- Median purity
- —
- Lowest price per mg
- $119.00
- peer median $138.99
- Publications located
- 1.2k
- researched since 1987
Source: PepIndex, an independent index of research-peptide vendors. No vendor can pay for a rank, every score is computed by a published formula, and every figure links to the document it was read from.
No indexed vendor publishes a Follistatin-344 certificate naming a laboratory this index could check, so no vendor can be called well-tested for it yet. The lowest listed price is $119.00 per mg at True Research Labs, against a peer median of $138.99. 3 vendors carrying Follistatin-344 are compared below. 0 publish at least one certificate naming a checkable laboratory, no lot record is on file, and none is an independently commissioned assay. Figures are PepIndex's own: it is an independent index of research-peptide vendors, no vendor can pay for a rank, and each figure links to the certificate it was read from.
Every vendor carrying Follistatin-344
| # | Vendor | Score here | Price / mg | Lots | Newest test | Laboratory | Mean purity | Label gap | Reports |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Northline LabsISO/IEC 17025 | 81.595% | $138.99 (100%) | 0 | — | — | — | — | no reportVisit site |
| 2 | True Research Labs | 66.968% | $119.00 (86%) | 0 | — | — | — | — | no reportVisit site |
| 3 | Biotech Peptides | 58.860% | $162.00 (117%) | 0 | — | — | — | — | no reportVisit site |
Independent assays
No independently commissioned assay of Follistatin-344 is on file. No certificate for it has been indexed at all. PepIndex does not yet commission its own assays, so nothing on this page establishes what is in a vial beyond the vendor’s own certificate. A record moves into this section the moment an assay commissioned by anyone other than the seller is indexed.
Laboratories used
No certificate for Follistatin-344 names a laboratory this index could identify.
Every certificate record
No certificate record for Follistatin-344 is indexed. Either no vendor publishes one, or those published could not be read without an account.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 1987 — 39 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
1,215 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
No certificate records indexed yet — nothing recorded yet
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
No certificate records indexed yet — nothing recorded yet
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
3 of 3 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
No certificate records indexed yet — nothing recorded yet
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is Follistatin-344?
An isoform of follistatin, an endogenous antagonist of myostatin and related TGF-beta ligands. Its published literature is predominantly preclinical and concerns muscle, fibrosis and reproductive biology.
Studied in published research for muscle growth and myostatin inhibition.
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
PepIndex records the size and shape of the published research footprint only. It does not evaluate or summarise clinical significance, does not describe administration, and nothing here is a claim of safety or efficacy.
- Follistatin — The international journal of biochemistry & cell biology (1998)
Peer-reviewed article indexed in PubMed, published in The international journal of biochemistry & cell biology (1998).
- Follistatin drives neuropathic pain in mice through IGF1R signaling in nociceptive neurons — Science translational medicine (2024)
Peer-reviewed article indexed in PubMed, published in Science translational medicine (2024).
- Fructose and follistatin potentiate acute MASLD during complete hepatic insulin resistance — Nature communications (2025)
Peer-reviewed article indexed in PubMed, published in Nature communications (2025).
- Follistatin and follistatin-like 3 in metabolic disorders — Prostaglandins & other lipid mediators (2023)
Peer-reviewed article indexed in PubMed, published in Prostaglandins & other lipid mediators (2023).
- Heparin-mediated dimerization of follistatin — Experimental biology and medicine (Maywood, N.J.) (2021)
Peer-reviewed article indexed in PubMed, published in Experimental biology and medicine (Maywood, N.J.) (2021).
- Activin/follistatin and atherosclerosis--a review — Journal of atherosclerosis and thrombosis (1998)
Peer-reviewed article indexed in PubMed, published in Journal of atherosclerosis and thrombosis (1998).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.